In the past week, TGTX stock has gone down by -7.92%, with a monthly decline of -12.63% and a quarterly surge of 26.75%. The volatility ratio for the week is 5.46%, and the volatility levels for the last 30 days are 5.61% for TG Therapeutics Inc The simple moving average for the past 20 days is -10.64% for TGTX’s stock, with a 23.72% simple moving average for the past 200 days.
Is It Worth Investing in TG Therapeutics Inc (NASDAQ: TGTX) Right Now?
The stock has a 36-month beta value of 2.27. Opinions on the stock are mixed, with 6 analysts rating it as a “buy,” 2 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for TGTX is 140.52M, and at present, short sellers hold a 18.50% of that float. On January 14, 2025, the average trading volume of TGTX was 2.92M shares.
TGTX) stock’s latest price update
The stock price of TG Therapeutics Inc (NASDAQ: TGTX) has dropped by -4.19 compared to previous close of 28.88. Despite this, the company has seen a fall of -7.92% in its stock price over the last five trading days. globenewswire.com reported 2025-01-09 that NEW YORK, Jan. 09, 2025 (GLOBE NEWSWIRE) — TG Therapeutics, Inc. (NASDAQ: TGTX), today announced that Michael S. Weiss, the Company’s Chairman and Chief Executive Officer, will present at the 43rd Annual J.P.
Analysts’ Opinion of TGTX
Many brokerage firms have already submitted their reports for TGTX stocks, with TD Cowen repeating the rating for TGTX by listing it as a “Buy.” The predicted price for TGTX in the upcoming period, according to TD Cowen is $50 based on the research report published on October 29, 2024 of the previous year 2024.
Goldman, on the other hand, stated in their research note that they expect to see TGTX reach a price target of $12, previously predicting the price at $16. The rating they have provided for TGTX stocks is “Neutral” according to the report published on August 02nd, 2023.
Jefferies gave a rating of “Buy” to TGTX, setting the target price at $40 in the report published on June 26th of the previous year.
TGTX Trading at -10.91% from the 50-Day Moving Average
After a stumble in the market that brought TGTX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -24.89% of loss for the given period.
Volatility was left at 5.61%, however, over the last 30 days, the volatility rate increased by 5.46%, as shares sank -12.58% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +7.62% upper at present.
During the last 5 trading sessions, TGTX fell by -7.92%, which changed the moving average for the period of 200-days by +79.21% in comparison to the 20-day moving average, which settled at $30.97. In addition, TG Therapeutics Inc saw -8.07% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at TGTX starting from Power Sean A, who sale 11,337 shares at the price of $30.29 back on Jan 03 ’25. After this action, Power Sean A now owns 670,632 shares of TG Therapeutics Inc, valued at $343,443 using the latest closing price.
Power Sean A, the CFO of TG Therapeutics Inc, sale 10,021 shares at $28.53 during a trade that took place back on Jan 06 ’25, which means that Power Sean A is holding 660,611 shares at $285,939 based on the most recent closing price.
Stock Fundamentals for TGTX
Current profitability levels for the company are sitting at:
- -0.0 for the present operating margin
- 0.88 for the gross margin
The net margin for TG Therapeutics Inc stands at -0.05. The total capital return value is set at -0.0. Equity return is now at value -8.05, with -3.13 for asset returns.
Based on TG Therapeutics Inc (TGTX), the company’s capital structure generated 0.56 points at debt to capital in total, while cash flow to debt ratio is standing at -0.12. The debt to equity ratio resting at 1.27. The interest coverage ratio of the stock is -0.03.
Currently, EBITDA for the company is 26.1 million with net debt to EBITDA at 9.85. When we switch over and look at the enterprise to sales, we see a ratio of 16.49. The receivables turnover for the company is 2.29for trailing twelve months and the total asset turnover is 0.45. The liquidity ratio also appears to be rather interesting for investors as it stands at 4.59.
Conclusion
To sum up, TG Therapeutics Inc (TGTX) has seen a mixed performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
